Abstract library

837 results for "disease-free survival".
#2886 Risk Factors for Short Recurrence-Free Survivals after Resection of PanNET Liver Metastasis: Single Institutional Analysis
Introduction: Although the treatment of PanNEN has improved survivals with development of pharmacotherapy recently, surgery is the first choice if curative resection is expected to be achieved. However, most of the patients undergo recurrence after resection of the liver metastasis even after curative resection. Therefore, it is important to identify who gains longer RFS by resection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: M.D., Ph.D. Toshihiko Masui
Authors: Masui T, Anazawa T, Nagai K, Sato A, ...
#2729 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in a Single Institute in North Africa over the Last 16 Years
Introduction: Because of the low incidence, nonspecific symptoms at presentation, lack of awareness, and non-uniform classifications, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remains a poorly understood disease, and delayed diagnosis is common among patients with GEP-NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira
#2954 Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors
Introduction: Different treatment modalities have been considered for patients with malignant advanced neuroendocrine tumors(NETs) of the pancreas and duodenum.Aggressive surgery remains a controversial yet an efficacious antitumor therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Doctor Azka Athar
Authors: Athar A, ...
#2758 Survival According to Therapy Regimen for siNET: Data from 145 Patients from a German Tertiary Referral Centre, Preliminary Results
Introduction: Scarce data exists for therapy regimens other than SSRA and PRRT for siNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Christine Koch
Authors: Bambey C, Koch C, Filmann N, Husmann G, ...
#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)
Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Sonja Levy
Keywords: SI-NET, Nomogram, Survival
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt
#2893 Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools
Introduction: Clinical prediction tools aggregate patient and disease information to predict outcomes. Little is known about gastrointestinal neuroendocrine tumors (GI-NET) prediction tools accuracy and utility.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Julie Hallet
Authors: Hallet J, Ho G, Beyfuss K, Chan D, ...
#2792 Post-Transplant Recurrence of Neuroendocrine Tumors
Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2717 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms
Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Esben Andreas Carlsen
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak